Hycor Gets FDA Approval to Market New Allergy Test
GARDEN GROVE — Hycor Biomedical Inc. has received approval from the federal Food and Drug Administration to market a line of single-day allergy tests.
The new tests cut in half the time it takes to receive results from an enzyme immuno-assay test, the most common type of test used in doctors’ offices, said Reg Jones, a company spokesman.
Hycor does not necessarily expect to increase sales with the new test; it already has revenue of $7 million in the market.
“This will keep us a step ahead of our competitors,” Jones said. “We are trying to prevent a loss of sales, and perhaps get others to switch.”
Hycor’s stock closed at $7.13 a share Thursday, up 75 cents in over-the-counter trading.
Hycor is a Garden Grove biotechnology company that specializes in medical diagnostic products. Jones said the company will apply the single-day test to each of its 250 tests for allergens.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
